e-learning
resources
London 2016
Sunday, 04.09.2016
Drugs, bugs, BMI, and other problems in paediatric asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Once-daily tiotropium Respimat® add-on therapy improves PEF in participants aged 6-17 years with symptomatic asthma
Eckard Hamelmann (Bielefeld, Germany), Eckard Hamelmann, Christian Vogelberg, Jonathan A. Bernstein, Thomas Harper III, Petra Moroni-Zentgraf, Michael Engel, Georges El Azzi, Helen Finnigan, Stanley J. Szefler
Source:
International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma
Session:
Drugs, bugs, BMI, and other problems in paediatric asthma
Session type:
Thematic Poster
Number:
1241
Disease area:
Airway diseases, Paediatric lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Eckard Hamelmann (Bielefeld, Germany), Eckard Hamelmann, Christian Vogelberg, Jonathan A. Bernstein, Thomas Harper III, Petra Moroni-Zentgraf, Michael Engel, Georges El Azzi, Helen Finnigan, Stanley J. Szefler. Once-daily tiotropium Respimat® add-on therapy improves PEF in participants aged 6-17 years with symptomatic asthma. Eur Respir J 2016; 48: Suppl. 60, 1241
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Safety of tiotropium Respimat® add-on therapy in patients aged 6-17 years with symptomatic asthma
Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma
Year: 2016
Tiotropium Respimat® add-on therapy in children with symptomatic asthma
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015
LATE-BREAKING ABSTRACT: Once-daily tiotropium Respimat® add-on therapy improves lung function in children with moderate symptomatic asthma
Source: International Congress 2016 – Living with asthma around the globe
Year: 2016
LATE-BREAKING ABSTRACT: Safety and tolerability of once-daily tiotropium Respimat® add-on therapy in children with moderate symptomatic asthma
Source: International Congress 2016 – Living with asthma around the globe
Year: 2016
Efficacy of tiotropium Respimat® in adults with moderate asthma, by baseline LTRA use
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015
Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Efficacy and safety of inhaled corticosteroids in combination with a long-acting beta2-agonist in asthmatic children under age 5
Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma
Year: 2016
Add-on effects of long-acting beta
2
-agonists salmeterol inhaler
vs
tulobuterol patch in adult patients with mild-to-moderate asthma
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthma
Source: International Congress 2015 – Immune mechanisms in the human lung
Year: 2015
Efficacy and safety of once-daily (OD) fluticasone furoate (FF) in adults and adolescents with moderate-to-severe persistent asthma
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Efficacy and safety of once-daily (OD) fluticasone furoate (FF) 50mcg over 24 weeks in adults and adolescents with persistent asthma
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Safety of tiotropium in pre-school children with symptomatic persistent asthma
Source: International Congress 2016 – Paediatric asthma: lessons learned from studies with large sample sizes and multi-centre drug studies
Year: 2016
The add-on effect of tiotropium bromide to ICS/LABA combination inhaler for the patients with severe uncontrolled asthma
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Once-daily tiotropium respimat add-on to ICS±LABA improves control across asthma severities
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Once-daily QVA149 improves symptom scores in patients with COPD
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept